Landmark Research Heralds New Era in Dog Heart Treatment and Lon

Landmark research heralds new era in dog heart treatment and longer life for dogs

Veterinarians and dog owners are today welcoming new research that delivers the promise of an extended happy life together for millions of dog owners and their pets. The three-year study demonstrates that dogs suffering from the most common type of heart failure live on average 91% (267 days vs. 140 days) longer when treated with the product Vetmedin® (pimobendan) compared with another common treatment option.

Results from the QUEST (Quality of Life and Extension of Survival Time) study, published in the current issue of the Journal of Veterinary Internal Medicine, mark a significant milestone in canine cardiac health. Experts report that 25% of all small to medium-sized dogs over the age of seven are likely to suffer from heart disease at some point in their life2, and 75% of those cases are caused by myxomatous mitral valve disease (MMVD)3, sometimes known as "valvular insufficiency" or "endocardiosis".

To view Multimedia News Release, go to http://www.prnewswire.com/mnr/boehringeringelheim/34774/